{
    "relation": [
        [
            "",
            "Number of Participants Analyzed [units: participants]",
            "Part I: Change in Health Related Quality of Life Over Time by Child Health Questionnaire (CHQ-PF50) [units: Score on a scale] Median (Full Range)",
            "Physical Health Score",
            "Psychosocial Health Score"
        ],
        [
            "Canakinumab",
            "125",
            "",
            "21.8050 (-21.554 to 62.309)",
            "8.2223 (-21.710 to 38.854)"
        ]
    ],
    "pageTitle": "Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00889863?sect=Xi015&view=results",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988458.74/warc/CC-MAIN-20150728002308-00068-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 864367215,
    "recordOffset": 864351947,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Period 1: \u00a0 Part I: Open Label Participant Flow for 2 periods Participants in Part II received placebo matching canakinumab subcutaneous injection every 4 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and \u22640.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was \u22640.2 mg/kg participants continued to maintain their current dose for the remainder of Part II. Placebo In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or Placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and \u2264 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was \u2264 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II. Canakinumab Description \u00a0",
    "textAfterTable": "Entered Part Ic \u00a0 \u00a0 92 [2] \u00a0 0 \u00a0 Entered Part 1d \u00a0 \u00a0 103 \u00a0 \u00a0 0 \u00a0 COMPLETED \u00a0 \u00a0 100 \u00a0 \u00a0 0 \u00a0 NOT COMPLETED \u00a0 \u00a0 77 \u00a0 \u00a0 0 \u00a0 Death \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 4 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 Unsatisfactory therapeutic effect \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 72 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}